Amanta Healthcare Limited (NSE: AMANTA, BSE: 544502) reported steady revenue growth and improved profitability for the quarter and nine months ended Dec. 31, 2025, supported by operating discipline, export-led growth and balance-sheet deleveraging, according to the company’s Q3 & 9M FY26 investor presentation.
Q3 FY26 financial performance
Revenue for the quarter rose 9.8% year on year to ₹75 crore. Operating EBITDA stood at ₹15 crore, with margins at 20.62%, reflecting cost control and improved operating leverage. Net profit increased 8.1% year on year to ₹5 crore, and the PAT margin stood at 6.21%.
The company said growth was driven by sustained demand across sterile liquid products, including IV fluids and small-volume parenterals, alongside higher export mix.
Nine-month FY26 snapshot
For the nine months ended Dec. 31, 2025, revenue increased 4.0% year on year to ₹211 crore. EBITDA rose 6.1% to ₹45 crore, with margins improving 42 basis points to 21.31%. Profit after tax increased 51.3% to ₹9 crore, reflecting margin normalization and operating leverage. The PAT margin expanded by 139 basis points to 4.43% over the period.
Business mix and capacity utilisation
Amanta is a niche manufacturer of sterile liquids, serving six therapeutic segments including IV fluids, formulations, diluents & injectables, ophthalmics, respiratory and irrigation solutions. The product portfolio comprises 47 products marketed across 120 international jurisdictions, with exports to 21 countries.
Capacity utilisation across parenteral lines remained high in FY25, with LVP, SVP and SteriPort lines operating near peak levels, indicating sustained demand visibility. The company’s flagship SteriPort IV fluid brand accounts for about 44% of revenue and operates at around 91% utilisation, supported by ISBM technology and two-port closure systems designed for sterile administration.
Expansion plans and growth roadmap
The company outlined capacity expansion plans to scale high-margin SteriPort (LVP) and SVP capacities, with incremental capacity targeted to come on stream in FY27. Management expects the new LVP line to lift installed capacity to 12 crore bottles and generate incremental revenue of ₹110–120 crore annually, with EBITDA margin expansion of 3–4 percentage points post-commissioning.
Amanta is also investing in complex dosages and niche molecules across anti-infectives, respiratory care and ophthalmics to expand wallet share. Management targets a revenue CAGR of over 20% over the next two years and EBITDA margins of 25%+ as new capacities ramp up.
Exports, ESG and cost optimisation
Exports accounted for about 32% of revenue, with domestic branded generics contributing the balance. The company plans to expand into regulated markets, including the UK, Zimbabwe, Sudan, Cambodia, the Philippines and Ethiopia, supported by a growing portfolio of registrations.
To structurally lower power costs, Amanta is setting up a 10.8 MW captive solar plant, with commissioning targeted in Q1 FY27. The project is expected to deliver annual power cost savings of about ₹9 crore, improving EBITDA margins over the medium term, while strengthening the company’s ESG profile.
Balance sheet and deleveraging
Amanta highlighted aggressive deleveraging over the past two years. Debt-to-equity declined from 3.43x in FY23 to 2.02x in FY25, supported by repayment of non-convertible debentures and equity infusion via a private placement in FY25. The turnaround in profitability further strengthened net worth.
Summary
Amanta Healthcare delivered steady Q3 FY26 growth and a sharp improvement in nine-month profitability, supported by margin expansion, exports and operating discipline. High utilisation across core lines, planned capacity additions in LVP and SVP, and investments in renewable energy position the company for margin-led growth as new capacities come on stream in FY27.